Here is Why Ocular Therapeutix (OCUL) is Highly Favored by Hedge Funds

Ocular Therapeutix Inc. (NASDAQ:OCUL) is one of the 7 best small-cap healthcare stocks to buy according to hedge funds.

On March 3, Tazeen Ahmad from Bank of America Securities increased the price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) from $24 to $27 while maintaining a Buy rating on the stock. This results in a revised upside potential of more than 257% for investors.

wavebreakmedia/Shutterstock.com

According to Ahmad, a thorough examination of the Phase 3 SOL1 trial results offers compelling evidence in favour of the approval and risk reduction that the diabetic retinopathy program offers through clarifying important questions.

On March 3, Clear Street raised its price target on Ocular Therapeutix Inc. (NASDAQ:OCUL) from $21 to $28. The firm maintained its Buy rating on the shares. Clear Street cited positive data from the SOL-1 trial, noting the results support Axpaxli’s potential to deliver durable control in wet AMD.

Clear Street added that the therapy could address a key unmet need around dosing intervals, with strong efficacy and a favorable safety profile supporting a more constructive outlook.

Ocular Therapeutix Inc. (NASDAQ:OCUL) focuses on developing and commercializing therapeutics for different eye conditions, including retinal diseases, using its bioresorbable hydrogel-based formulation technology. Its portfolio includes DEXTENZA, AXPAXLI in phase 3 of clinical trial, and OTX-TIC in phase 2 of clinical trial.

While we acknowledge the risk and potential of OCUL as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OCUL and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.